The rise of Sildenafil initially fueled a boom for major pharmaceutical companies, however recent developments present a murky scenario for shareholders. Lower-cost versions are eroding earnings, and ongoing legal battles add additional risk to the landscape. While specific companies may still see gains from adjacent services, the broader trend sug